Thermosome

Thermosome is a clinical-stage drug development company focused on targeted tumor therapy combined with immune stimulation for improved cancer therapy. At its core is a novel, proprietary tumor targeting approach that allows for significantly increased local drug concentrations and improved tumor penetration to achieve improved clinical treatment efficacy. The lead candidate THE001 is a thermosensitive formulation of doxorubicin being developed in soft tissue sarcoma.

Press releases

Press
6. April 2016
Thermosome raises €4.6m with first financing round and a research grant from the German government
Thermosome GmbH, an emerging biopharmaceutical company, today announces the closing of its first financing round, raising net proceeds of approximately €1.9 million from funds managed by High-Tech Gründerfonds Management GmbH and Bayern Kapital GmbH, respectively, as well as a group of private investors. This first financing round is substantially enlarged by a recently approved grant from the German Federal Ministry of Education and Research (BMBF) providing additionally €2.7 million over
 

Info & Contact

Dr. Pascal Schweizer
Phone:
+49 89 7167760-31
Web:
www.thermosome.com

Address

Am Klopferspitz 19 (IZB)
82152 Planegg/Martinsried

In portfolio

15. Oct 2015

Sector

HTGF Manager

 
Dr. Caroline Fichtner, Principal / Authorized Signatory